AI Article Synopsis
- Liver cancer is a major cause of cancer deaths, and using beta-emitting radionuclides in targeted treatments like Ho-hydroxyapatite (Ho-HA) is a promising approach.
- The study estimated radiation absorbed doses of Ho-HA in the liver and other tissues using specific calculation methods, revealing that over 84% of the dose concentrated in liver tissue.
- Ho-HA treatment allows for high doses to the tumor while minimizing exposure to healthy tissues, suggesting its potential effectiveness for liver cancer therapy.
Article Abstract
Objectives: Liver malignancies are among the most prevalent causes of cancer-related deaths worldwide. Intra-arterial administration of particulates labeled with beta-emitting radionuclides is one of the non-surgical promising modalities for the treatment of liver cancer.
Methods: In this work, the radiation absorbed dose of Ho-hydroxyapatite (Ho-HA) radiopharmaceutical was estimated for adult men based on biodistribution data in normal Wistar rats. The MIRD dose calculation method and the Sparks and Aydogan methodology were applied.
Results: The results show that more than 84% of the absorbed dose is localized in liver tissue (7.35 mGy MBq). Also, radiation absorbed doses of Ho-HA for red bone marrow, osteogenic cells, and spleen tissues were estimated to be about 0.18, 0.38, and 0.24 mGy MBq, respectively. The maximum administrated activity was obtained at 87.5 MBq kg of body weight with an effective dose of 0.39 mSv MBq. The maximum tolerable dose (MTD) for liver tissue was 6.13 GBq (165.56 mCi).
Conclusion: This study indicated that Ho-HA can provide an impressive dose for liver cancer malignancies with an insignificant dose to healthy tissues.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11682468 | PMC |
| http://dx.doi.org/10.22038/aojnmb.2024.79679.1560 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!